Navigation Links
GenVec Announces Update of Safety and Efficacy Data from Pivotal,Phase II/III PACT Study of TNFerade at ASCO

nge Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

Contact

GenVec, Inc.
Sharon L. Weinstein, 240-632-5511
Director, Investor Relations
& Corporate Communications
sweinstein@genvec.com


'"/>




Page: 1 2 3 4

Related medicine technology :

1. GenVec Presents Research on New Ad35 Adenovector at ARVO
2. GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:5/16/2008)...r Novel Approach to Blood ...wire-FirstCall/ -- Pharmacopeia (Nasdaq:,PCOP), an...el small,molecule therapeutics, announced today th...or Antagonist (DARA), showed statistically signifi... in patients with mild to,moderate hypertension. P...
(Date:5/15/2008)...- Eisai Corporation of North,America announced tod...out,compounds in the company,s oncology pipeline, ...h have been accepted for presentation at the,44th ... Oncology (ASCO),taking place in Chicago from May... on Eisai marketed products and,investigational co...
(Date:5/15/2008)...ety profile of BSI-201 in subjects...May 15 /- BiPar Sciences, Inc., a,pri...ovel cancer therapies,today announced that data s...e presented at the 2008 American Society of Clinic...will be presented from the first in human Phase 1 ...
(Date:5/15/2008)...rstCall/ -- Cytopia Limited,(ASX: CYT) today annou...ntation on CYT997 at the 2008 Annual Meeting of th...l be accessible to the public via ASCO,s,website ... (US EDT)., The oral presentation, entitled "Phas...scular disrupting agent, in patients with advanced...
Breaking Medicine Technology:Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Tata Consultancy Services to Support Roches Global Capacity Building Initiative 455 1Tata Consultancy Services to Support Roches Global Capacity Building Initiative 455 2Tata Consultancy Services to Support Roches Global Capacity Building Initiative 455 3Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 1Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 2Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 3Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 4Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 5Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 6Nanotechnology 3A Whats that 3F 244 1Nanotechnology 3A Whats that 3F 244 2Avocados may help prevent oral cancer OSU study shows 443 1Avocados may help prevent oral cancer OSU study shows 443 2
... in Evaluating Drug,Efficacy; Dr. H. Bryan Brewer,...EASANTON, CA, Mar 30, 2007 (MARKET WIRE via COMTEX...PD) Dr. H. Bryan Brewer, Jr.,Chief Scientific Dir...wide range of presentations at the recent American...s that the rationale for HDL,being the next, most ...
...al and Social,Performance, COLORADO SPRINGS, C... treatment with INVEGA(TM) (paliperidone),Extend...on for,schizophrenia, helped many patients effec... improvements in personal and social,functioning...el, international,clinical trial sponsored by Ja...
Other Medicine Technology:Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 2Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 3Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 4Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 5Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 2Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 3Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 4Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 5Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 6
(Date:5/16/2008)...-- Patients who feel better live longer, say Mayo ... Cancer Treatment Group (NCCTG), in study results ... of the American Society of Clinical Oncology (ASC...dys lead author, Angelina Tan, says the results sh...vival. , Quality of life appears to affect the s...
(Date:5/16/2008)...ith deficiency were more likely to suffer recurren...(HealthDay News) -- Women with breast cancer who h...s are more likely to have a recurrence or to die f...singly, the researchers also found that only 24 pe...in D when they were diagnosed. , "This study fo...
(Date:5/16/2008)... May 16 /PRNewswire-FirstCall/ -- IDM Pharma, Inc....ta presentations evaluating,the Company,s lead pro...American Society of Clinical Oncology (ASCO) annua...ort improved survival for patients with metastatic...tients with non-small lung,cancer treated with IDM...
(Date:5/15/2008)...3 and ABT-869 to be Promising in Targeting Cancer ...ms, ABBOTT PARK, Ill., May 15 /PRNewswire-FirstCa... clinical trial data of several investigative,comp...ear,s American,Society of Clinical Oncology (ASCO)...The presentations include ABT-263, a Bcl-2 family ...
Breaking Medicine News(10 mins):Health News:Cancer patients' quality of life directly relates to their survival 2Health News:Cancer patients' quality of life directly relates to their survival 3Health News:Low Levels of Vitamin D Spell Trouble for Breast Cancer Patients 2Health News:Low Levels of Vitamin D Spell Trouble for Breast Cancer Patients 3Health News:IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting 2Health News:IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting 3Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 2Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 3Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 4Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 5Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 6
...chers at the Hopkins University felt that intense ...anagement. Feeling tired all the time may be a sig...e part and parcel of an overwhelmingly busy life. ...u down, ask your doctor to investigate.// Conditi...
... therapy has been quite popular in recent years. B...ince decades. The best way to cure that pain in yo.... Researchers felt that this form of therapy is co... or treatment// with pain medications counseling a...
...ing to a new study, shows that ulcer rates among d...ong those wearing ordinary good quality footwear. ...d foot care is an essential// part of managing the...pical in diabetes leaves the foot vulnerable to ul...
...ing to a new study, zinc supplements could play a ...om diarrhea around the world. Researchers who test...in nearly 1,650 Nepalese youngsters found zinc red...lasting more than seven days by 35 percent to 45 p...
Other Medicine News:
...: The HF-compatible V series from Pentax, the stan...asured., ,The HF-compatible series of fibre bronc...V and FB-15V models along with the very slim FB-10... quality thanks mainly to the higher resolution an...
...m the latest 60 series bronchoscopes., ,Olymp... providing clinicians with superior specifications...ressive range of fiberoptic instruments for diagno...he demands of increasing peripheral bronchoscopy.,...
The BRO-YP2 is Fujinon's pediatric fiberoptic bronchoscope. Its small outside diameter allows for more comfortable transnasal insertion. The standard 2.0mm channel provides sufficient suction and acc
...m the latest 60 series bronchoscopes., ,Olymp... providing clinicians with superior specifications...ressive range of fiberoptic instruments for diagno...he demands of increasing peripheral bronchoscopy.,...
Medicine Products: